PET/CT imaging and dosimetry as predictive factors for treatment response of the 177Lu-DOTA-TATE therapy

PET/CT imaging and dosimetry as predictive factors for treatment response of the 177Lu-DOTA-TATE therapy - DOTADOSE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00004376

Enrollment

Registered

2012-09-20

Start date

2012-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C75.9

Interventions

Group 1: Observation Group: From patients (subject group), which have metastasized non-operable neuroendocrine tumors and therefore got a 177Lu-DOTA-TATE therapy, we evaluate the dosimetric data of t

non-interventional study.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: indication for 177Lu-DOTATATE therapy: - well differenciated, metastasized neuroendocrine tumors or carcinoma, which overexpress somatostatin receptors subtyp 2 (positive pretherapeutic 68Ga-DOTA-TATE PET/CT) and which are not able to treat curative, - meningiomas, which overexpress somatostatin receptors subtyp 2 and which are not able to treat with an alternative treatment. pro DOTATATE therapy: - progress of tumor, "firt line, second line therapy", - metastasis, not local restricted to the liver, - significant overexpression of somatostatin receptor subtyp 2, - normal kidney function. - able and willing to give informed consent

Exclusion criteria

Exclusion criteria: - renal insufficiency, creatinine >1.5 mg/dl and/or GFR 20%

Design outcomes

Secondary

Measure	Time frame
SUVmax [g/ml], tumor doses [Gy/GBq], kidney doses [Gy/GBq], correlation between conventional dosimetry and voxel-based dosimetry	—

Primary

Measure	Time frame
triple phase CT scan; decrease in lesion-volume [ml]	—

Countries

Germany

Contacts

Public ContactWolfgang Weber

Universitätsklinikum Freiburg, Abteilung Nuklearmedizin

wolfgang.weber@uniklinik-freiburg.de+49 761 270 39160

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026